Axon Enterprise (NASDAQ:AXON) Earns "Market Outperform" Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Axon Enterprise (NASDAQ:AXON - Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $375.00 target price on the biotechnology company's stock.

Several other brokerages also recently weighed in on AXON. StockNews.com downgraded shares of Axon Enterprise from a buy rating to a hold rating in a report on Thursday, March 14th. Morgan Stanley boosted their price objective on shares of Axon Enterprise from $285.00 to $310.00 and gave the stock an equal weight rating in a report on Friday, April 26th. Argus assumed coverage on shares of Axon Enterprise in a research report on Wednesday, March 13th. They set a buy rating and a $380.00 target price on the stock. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a buy rating in a research report on Wednesday, February 28th. Finally, TheStreet cut Axon Enterprise from a b rating to a c+ rating in a report on Tuesday, February 27th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $327.00.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded down $14.91 during trading hours on Tuesday, hitting $312.73. 1,021,233 shares of the company were exchanged, compared to its average volume of 477,590. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average of $309.95 and a 200-day moving average of $266.41. Axon Enterprise has a 1 year low of $175.37 and a 1 year high of $329.87. The stock has a market capitalization of $23.60 billion, a price-to-earnings ratio of 134.54 and a beta of 0.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Monday, May 6th. The biotechnology company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.20. The business had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business's quarterly revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.51 earnings per share. As a group, analysts expect that Axon Enterprise will post 2.44 EPS for the current fiscal year.

Institutional Trading of Axon Enterprise

A number of institutional investors have recently modified their holdings of the company. ICA Group Wealth Management LLC purchased a new position in Axon Enterprise in the 4th quarter worth approximately $26,000. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise in the 1st quarter worth approximately $31,000. BKM Wealth Management LLC purchased a new position in Axon Enterprise in the 4th quarter worth approximately $32,000. First PREMIER Bank purchased a new position in Axon Enterprise in the 1st quarter worth approximately $33,000. Finally, Key Financial Inc boosted its holdings in Axon Enterprise by 367.6% in the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 125 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.